Insiders · CNTA

Arjun Goyal

Director at Centessa Pharmaceuticals plc (CNTA)

Arjun Goyal has filed 6 insider reports with the SEC since July 2022, as director at Centessa Pharmaceuticals plc (CNTA). Arjun Goyal made no open-market purchases or sales in the last 12 months. The latest filing, on June 24, 2026, reports sale back to the company at Centessa Pharmaceuticals plc (CNTA).

Filings
6
Companies
1
Bought on market
$5.87M
Sold on market
None

Companies where Arjun Goyal is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Centessa Pharmaceuticals plc logo
CNTA
Centessa Pharmaceuticals plc
Director$5.87M$12.68Jun 24, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Arjun Goyal with

Other insiders at the same companies

Questions about Arjun Goyal

What is Arjun Goyal's role at Centessa Pharmaceuticals plc?
Arjun Goyal reports to the SEC as director at Centessa Pharmaceuticals plc (CNTA), according to the latest filing on June 24, 2026.
Has Arjun Goyal bought or sold stock recently?
The most recent open-market purchase was on May 16, 2025: bought 462,585 shares of Centessa Pharmaceuticals plc (CNTA) for $5.87M at an average of $12.68.
How do I get alerts when Arjun Goyal files?
Follow Arjun Goyal on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Arjun Goyal (SEC CIK 0001861844). Totals count each trade once, skipping amendments whose original is on file, from Jul 5, 2022 on. View on SEC EDGAR · Get this as JSON